摘要:
The invention provides a modified release lercanidipine pharmaceutical composition comprising at least one waxy substance and a therapeutically effective amount of lercanidipine, wherein oral administration of the modified release lercanidipine pharmaceutical composition to a patient results in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for the full time period of about 24 hours after administration of the composition to the patient.
摘要翻译:本发明提供了包含至少一种蜡质物质和治疗有效量的氯卡地平的改良释放氯卡地平药物组合物,其中向患者口服给予改良释放的氯卡地平药物组合物导致平均lercanidipine血药浓度大于0.5ng / ml 在将组合物施用于患者后约24小时的全部时间段。
摘要:
This invention relates to pharmaceutical formulations for the transmucosal delivery of 4-amino-6,7-dimethoxy-2-{4-[(2-isopropyl-6-methoxyphenoxy)acetyl]-1-piperazinyl}quinazoline (Rec 15/2615), which has the formula: The formulations are useful in methods for enhancing the sexual act for females, including treatment of female sexual dysfunction.
摘要:
Orally administrable pharmaceutical preparation containing an active ingredient to be released in the lower part of the gastrointestinal tract, i.e. in the large intestine, and especially colon, consisting of a core containing a therapeutically active substance and coated with three protection layers at different solubility. The manufacturing and the use of these preparations are also described.